期刊文献+

藤黄酸调节肺腺癌A549细胞甾体类受体共激活因子3表达的意义 被引量:3

Effects of gambogic acid on the regulation of steroid receptor coactivator-3 in A549 cells
原文传递
导出
摘要 目的观察藤黄酸对人肺腺癌细胞株A549增殖和凋亡的影响,及其对甾体类受体共激活因子3(SRC-3)表达的调控作用。方法以不同浓度的藤黄酸处理人肺腺癌A549细胞,采用四甲基偶氮唑蓝(MTT)法检测细胞的增殖活性,Hoechst 33258染色法分析细胞凋亡的改变,共聚焦显微镜观察A549细胞中SRC-3蛋白的分布情况,Western blot和逆转录聚合酶链反应(RT-PCR)法检测藤黄酸对A549细胞中SRC-3 mRNA和蛋白表达的影响。结果藤黄酸能明显抑制A549细胞的增殖,其抑制作用呈时间和浓度依赖性,24和48h的半数抑制浓度(IC90)分别为(3.17±0.13)μmol/L和(1.85±0.08)μmol/L。藤黄酸能使A549细胞出现典型的细胞凋亡形态改变。空白对照组的A549细胞中,SRC-3 mRNA和蛋白均呈高表达,且主要分布于细胞核;经藤黄酸处理后,A549细胞中SRC-3 mRNA和蛋白的表达水平均明显下降。结论藤黄酸能明显抑制人肺腺癌细胞A549的增殖,并可能通过下调SRC-3 mRNA和蛋白的表达量而诱导A549细胞产生凋亡。藤黄酸有望成为治疗肺癌的新型靶点药物。 Objective To investigate the effects of gambogic acid (GA) on the proliferation inhibition and apoptosis induction in Human lung adenocarcinoma A549 cells in vitro, as well as the regulation of steroid receptor coactivator-3 (SRC-3) to explore the relationship between them. Methods The effect of GA on the growth of A549 ceils was studied by MTT assay. Apoptosis was detected by Hoechst 33258 staining. The localization of SRC-3 was determined by confocal laser scanning microscopy. Western blot and RT-PCR technique were applied to assess the expression of SRC-3. Results GA presented a striking proliferation inhibition potency on A549 cells in vitro, as well as apoptosis induction activity in a time- and dose-dependent manner. The IC50 value for 24 h was (3.17±0.13)μmol/L. Overexpression of SRC-3 was found in A549 ceils, whereas the SRC-3 protein and mRNA expression levels were significantly downregnlated in A549 ceils induced by GA in a dose-dependent manner. The location of SRC-3 was situated mainly in the cell nuclei. Conclusion GA exhibits a potent proliferation inhibition and apoptosis induction in human lung adenocarcinoma A549 cells ,which might correspond to the downregulation of the expression of SRC-3. Thus, it promises to be a new target drug for lung cancer treatment.
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2009年第11期810-814,共5页 Chinese Journal of Oncology
基金 国家自然科学基金(30472267)
关键词 藤黄酸 肺肿瘤 甾体类受体共激活因子3 基因表达调控 Gambogic acid (GA) Lung neoplasms SRC-3 Gene expression regulation
  • 相关文献

参考文献3

二级参考文献99

  • 1Konishi J,Yamazaki K,Kinoshita I,et al. Analysis of the response and toxicity to gefitinib of non-small cell lung cancer. Anticancer Res,2005,25:435-441.
  • 2Birnbaum A,Ready N. Gefitinib therapy for non-small cell lung cancer. Curr Treat Options Oncol,2005,6:75-81.
  • 3Mu XL,Li LY, Zhang XT, et al. Evaluation of safety and efficacy of gefitinib (‘iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme. BMC Cancer,2004,4:51.
  • 4Miller VA,Kris MG,Shah N,et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol,2004,22:1103-1109.
  • 5Chang GC,Yang TY,Chen KC,et al. Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol,2004,22:4646-4648.
  • 6Cella D,Herbst RS,Lynch TJ,et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol,2005,23:2946-2954.
  • 7Cappuzzo F,Hirsch FR,Rossi E,et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst,2005,97:643-655.
  • 8Barlesi F,Tchouhadjian C,Doddoli C,et al. CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy. Br J Cancer,2005,92:13-14.
  • 9Giaccone G,Herbst RS,Manegold C,et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial-INTACT 1. J Clin Oncol,2004,22:777-784.
  • 10Herbst RS,Giaccone G,Schiller JH,et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial-INTACT 2. J Clin Oncol,2004,22:785-794.

共引文献37

同被引文献18

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部